Homepage

We are a global leader in generic and biosimilar pharmaceuticals, committed to driving access to medicine
Nous sommes un leader mondial dans le domaine des médicaments génériques et des biosimilaires, et nous ...

Explore Novartis

Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics

Sandoz, a Novartis division, has signed an agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics. The agreement includes the global rights to three established brands (Zinnat®, Zinacef® and Fortum®)) in more than 100 markets. 

Novartis 2020 Financial Results

scientist and colleagues

Novartis announced fourth quarter and full year financial results for 2020 on January 26, 2021

Sandoz officially certified as Global Top Employer 2021

Sandoz, a Novartis division, is pleased to announce that it has been officially awarded “Global Top Employer 2021” certification for the third year in a row. This year, Sandoz was one of only 16 Top Employers recognized for their outstanding HR policies and practices worldwide by the Top Employers Institute.

 

Sandoz fait don d’hydroxychloroquine à la Belgique

Novartis a promis un don mondial allant jusqu’à 130 millions de doses d’hydroxychloroquine, un antipaludique, afin d’apporter son soutien à la lutte contre la pandémie du COVID-19. La Belgique est l'un des nombreux pays à bénéficier de ce don.

Chez Sandoz, nous découvrons de nouvelles solutions pour améliorer et prolonger la vie des personnes. Nous sommes à l’origine de nouvelles approches pour permettre aux patients, à travers le monde, d’accéder à des médicaments de grande qualité.